Innova Captab Q3 FY26 Revenue Surges 42.3% to ₹450.3 Cr, PAT Up 23.2%
Innova Captab reported Q3 FY26 revenue of ₹450.3 Cr, up 42.3% YoY. EBITDA grew 39.6% to ₹71.1 Cr, and PAT increased 23.2% to ₹42.1 Cr. For 9M FY26, revenue reached ₹1182.2 Cr (up 27.3%), EBITDA was ₹183.7 Cr (up 24.8%), and PAT was ₹102.8 Cr (up 4.2%).
The substantial double-digit growth in key financial metrics like revenue and profit, coupled with international regulatory certifications, indicates a strong positive impact on the company's performance and market position.
The company reported significant year-on-year growth in revenue, EBITDA, and Profit After Tax for both the quarter and the nine-month period, along with positive commentary from the Managing Director and successful international regulatory approvals.
Innova Captab Limited announced strong unaudited financial results for the third quarter and nine months ended December 31, 2025. For Q3 FY26, the company reported a revenue from operations of ₹450.3 crores, a significant year-on-year increase of 42.3% from ₹316.5 crores in Q3 FY25. EBITDA for the quarter grew by 39.6% to ₹71.1 crores from ₹50.9 crores, with an EBITDA margin of 15.8%. Profit After Tax (PAT) for the quarter stood at ₹42.1 crores, marking a 23.2% rise from ₹34.2 crores in the same period last year, with a PAT margin of 9.4%.
For the nine months ended December 31, 2025 (9M FY26), revenue from operations reached ₹1182.2 crores, up 27.3% from ₹928.9 crores in 9M FY25. EBITDA for the nine-month period was ₹183.7 crores, an increase of 24.8% from ₹147.1 crores in 9M FY25, with an EBITDA margin of 15.5%. The PAT for 9M FY26 was ₹102.8 crores, showing a 4.2% growth from ₹98.7 crores in 9M FY25, with a PAT margin of 8.7%.
Mr. Vinay Lohariwala, Managing Director of Innova Captab Limited, commented that the company delivered accelerated YoY revenue growth, reflecting disciplined execution, improved client engagement in the CDMO business, and strategic geographic expansion in the Branded Generics vertical. He also highlighted the recent receipt of GMP Compliance Certificates from UK-MHRA for their Cephalosporin, Baddi unit, and from PIC/s (SMDC, Ukraine) for the Jammu facility, which are testaments to their adherence to global quality standards and will expand their international market reach. The company is well-positioned to drive consistent, high-quality growth and remains committed to stakeholder value creation.
What to do with a filing like this
Innova Captab Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Innova Captab Limited. Read the original for the full detail.